Marjan Zare

Scopus Publications

The Association between Serum Biochemical Markers and Early Amniocentesis in Diagnosing Chromosomal Anomalies: A Cross-Sectional Study in Southern Iran, 2021-2022
Maryam Kasraeian, Mehdi Dianatpour, Marzie Zare, Marjan Zare, Azam Faraji, et al.
Iranian Journal of Medical Sciences, 2026
Background: Efforts to improve prenatal diagnosis of Down syndrome have been made, with amniocentesis representing an invasive procedure, and maternal serum biochemical markers are among the non-invasive options. This study aimed to examine the association between serum biochemical marker values and amniocentesis results in the prenatal diagnostics of Down syndrome in early pregnancy. Methods: In a cross-sectional study, data from pregnant women in the first trimester undergoing amniocentesis test for the diagnosis of fetal genetic diseases were collected during 2021-2022. Maternal weight, maternal age, gestational age at nuchal translucency (NT) scan, nasal bone (NB) status, and serum chemical biomarkers-including pregnancy-associated plasma protein-A (PAPP-A), and beta-human chorionic gonadotropins (β-hCG) were assessed. Results: Of 1,987 amniocentesis cases, 96.5% were normal, and 3.5% were abnormal. Down syndrome was present in approximately 3% of cases. Maternal weight was significantly lower in the abnormal amniocentesis group than in the normal group. After adjusting for maternal weight, maternal age, NT, and β-hCG were significantly higher in the abnormal amniocentesis group, whereas PAPP-A was lower. The NB status did not differ between groups. A PAPP-A level of <0.42 multiple of median (MoM) (sensitivity=90%, specificity=68%) and a β-hCG level of ≥1.52 MoM (sensitivity=76%, specificity=70%) acceptably predicted Down syndrome in abnormal amniocentesis cases. Among the 69 abnormal amniocentesis cases, 49 cases had Down syndrome; of these, 75.5% had a Down syndrome risk of ≤1:100. Conclusion: Both β-hCG and PAPP-A had independent diagnostic value in predicting Down syndrome in early pregnancy. It is recommended that a Down syndrome risk of up to 1:100 warrant direct amniocentesis, while cases with a risk greater than 1:100 should be offered non-invasive alternatives.
Serum amyloid A as a diagnostic marker for histologic chorioamnionitis in preterm premature rupture of membranes: A diagnostic accuracy study
Azam Faraji, Mitra Mehraban, Maryam Kasraeian, Mojgan Akbarzadeh-Jahromi, Homeira Vafaei, Nasrin Asadi, Zahra Oveisi, Marzieh Kasraie, Marjan Zare
International Journal of Reproductive Biomedicine, 2026
Background: Chorioamnionitis is an acute inflammation of the fetal membrane in mothers with preterm premature rupture of the membrane (PPROM). The diagnosis of chorioamnionitis is based on clinical findings; however, laboratory tests may help diagnose the disease.Objective: It aimed to evaluate the accuracy of maternal serum-amyloid A (SAA) protein levels in diagnosing histopathologic chorioamnionitis following PPROM mothers; secondarily, it assessed their accuracy for diagnosing clinical chorioamnionitis.Materials and Methods: In this diagnostic accuracy study, 94 PPROM pregnancies, referred to Namazi, Hafez, and Zeinabiyeh hospitals, Shiraz, Iran, from March 2022 to March 2023 were followed. All placentas were examined for histopathological evidence of chorioamnionitis, and participants were classified into 2 pathologic chorioamnionitis and normal placenta groups.Results: From the 94 participants, 50 (43.20%) were pathologically diagnosed with chorioamnionitis as pathologic chorioamnionitis group, and the remaining 44 (46.80%) belonged to control “normal placenta group”. In addition, 50% (25/50) of women with pathological chorioamnionitis were clinically diagnosed with chorioamnionitis as clinic chorioamnionitis group, and the remaining 50% (25/50) with no clinical signs of chorioamnionitis belonged to their control. Pathologic at-delivery SAA were more in the pathologic chorioamnionitis group compared with normal placenta group; adjusted odds ratio (95% confidence interval); 15.20 (2.62–88.20); the area under curve values (cutoff point, sensitivity, specificity, negative predictive value, positive predictive value, and accuracy) were 0.83 (> 0.54 mg/dl, 95%, 70%, 86%, 88%, and 84%) for pathologic at-delivery SAA. However, clinic at-delivery SAA did not significantly change between clinic chorioamnionitis group and not having clinic chorioamnionitis. A no-clinic chorioamnionitis PPROM mother could be chorioamnionitis one by a 50% chance, even with no clinical sign.Conclusion: Pathologic at-delivery SAA level could be a supplementary test in PPROM mothers. At-delivery SAA serial measurements and long-term evaluation of infants born to these mothers are recommended.
Rosuvastatin for Improving Fetal Growth Restriction in Pregnant Women: A Double-Blind Randomized Clinical Trial
Maryam Kasraeian, Fatemeh Askari, Homeira Vafaei, Nasrin Asadi, Azam Faraji, et al.
Iranian Journal of Medical Sciences, 2025
Background: Fetal growth restriction (FGR) results from uteroplacental insufficiency and currently lacks an absolute cure. Statins may offer therapeutic potential by addressing this insufficiency. This study aimed to investigate the effectiveness of rosuvastatin in improving the perinatal outcomes in FGR pregnancies. Methods: A double-blind, randomized placebo-controlled clinical trial was conducted on 78 FGR pregnancies referred to tertiary centers affiliated with Shiraz University of Medical Sciences (Shiraz, Iran) from January 21, 2023, to March 21, 2023. The participants were randomly divided into two groups using the block randomization method to receive either 5 mg rosuvastatin or placebo daily from FGR diagnosis until delivery. Evaluated outcomes included birth weight, umbilical artery pulsatile index reduction, fetal weight gain, vaginal delivery rate, preterm birth (PTB) incidence, 5-min Apgar score <7, neonatal death, neonatal intensive care unit admission, intraventricular hemorrhage, respiratory distress syndrome, necrotizing enterocolitis, and preeclampsia. The data were analyzed using regression models, reporting mean difference (95% CI), frequency (relative frequency), and odds ratio with 95% confidence interval (OR [95% CI]). Statistical significance was set at P<0.05. Results: The study included 34 subjects in the rosuvastatin group and 44 subjects in the placebo group, with no significant differences in baseline characteristics. However, the rosuvastatin group showed significantly better outcomes in birth weight (276.27 g, 95% CI=32.61-519.93, OR=1.002, 95% CI=1-1.003), umbilical artery pulsatililty index reduction (0.21 g, 95% CI=0.00-0.43, OR=6.600, 95% CI=1.680-25.930), fetal weight gain (312.51 g, 95% CI=90.50-534.52, OR=1.001, 95% CI=1-1.002), and vaginal delivery rate (6/34 [17.6%] vs. 1/44 [2.3%]; OR=9.210, 95% CI=1.050-80.680). Additionally, the rosuvastatin group had significantly lower PTB rates (15/34 [44.10%] vs. 30/44 [68.20%]; OR=0.370, 95% CI=0.150-0.930). Neonatal health status showed no significant differences between groups. Conclusion: IRCT20140317017035N8.
Whole-genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles
Jennifer E. Huffman, Jayna Nicholas, Julie Hahn, Adam S. Heath, Laura M. Raffield, Lisa R. Yanek, Jennifer A. Brody, Florian Thibord, Laura Almasy, Traci M. Bartz, Lawrence F. Bielak, Russell P. Bowler, Germán D. Carrasquilla, Daniel I. Chasman, Ming-Huei Chen, David B. Emmert, Mohsen Ghanbari, Jeffrey Haessler, Jouke-Jan Hottenga, Marcus E. Kleber, Ngoc-Quynh Le, Jiwon Lee, Joshua P. Lewis, Ruifang Li-Gao, Jian'an Luan, Anni Malmberg, Massimo Mangino, Riccardo E. Marioni, Angel Martinez-Perez, Nathan Pankratz, Ozren Polasek, Anne Richmond, Benjamin A. T. Rodriguez, Jerome I. Rotter, Maristella Steri, Pierre Suchon, Stella Trompet, Stefan Weiss, Marjan Zare, Paul Auer, Michael H. Cho, Paraskevi Christofidou, Gail Davies, Eco de Geus, Jean-François Deleuze, Graciela E. Delgado, Lynette Ekunwe, Nauder Faraday, Martin Gögele, Andreas Greinacher, He Gao, Tom Howard, Peter K. Joshi, Tuomas O. Kilpeläinen, Jari Lahti, Allan Linneberg, Silvia Naitza, Raymond Noordam, Ferran Paüls-Vergés, Stephen S. Rich, Frits R. Rosendaal, Igor Rudan, Kathleen A. Ryan, Juan Carlos Souto, Frank J. A. van Rooij, Heming Wang, Wei Zhao, Lewis C. Becker, Andrew Beswick, Michael R. Brown, Brian E. Cade, Harry Campbell, Kelly Cho, James D. Crapo, Joanne E. Curran, Moniek P. M. de Maat, Margaret Doyle, Paul Elliott, James S. Floyd, Christian Fuchsberger, Niels Grarup, Xiuqing Guo, Sarah E. Harris, Lifang Hou, Ivana Kolcic, Charles Kooperberg, Cristina Menni, Matthias Nauck, Jeffrey R. O'Connell, Valeria Orrù, Bruce M. Psaty, Katri Räikkönen, Jennifer A. Smith, Jose Manuel Soria, David J. Stott, Astrid van Hylckama Vlieg, Hugh Watkins, Gonneke Willemsen, Peter W. F. Wilson, Yoav Ben-Shlomo, John Blangero, Dorret Boomsma, Simon R. Cox, Abbas Dehghan, Johan G. Eriksson, Edoardo Fiorillo, Myriam Fornage, Torben Hansen, Caroline Hayward, M. Arfan Ikram, J. Wouter Jukema, Sharon L. R. Kardia, Leslie A. Lange, Winfried März, Rasika A. Mathias, Braxton D. Mitchell, Dennis O. Mook-Kanamori, Pierre-Emmanuel Morange, Oluf Pedersen, Peter P. Pramstaller, Susan Redline, Alexander Reiner, Paul M. Ridker, Edwin K. Silverman, Tim D. Spector, Uwe Völker, Nicholas J. Wareham, James F. Wilson, Jie Yao, David-Alexandre Trégouët, Andrew D. Johnson, Alisa S. Wolberg, Paul S. de Vries, Maria Sabater-Lleal, Alanna C. Morrison, Nicholas L. Smith
Blood, 2024
Genetic studies have identified numerous regions associated with plasma fibrinogen levels in Europeans, yet missing heritability and limited inclusion of non-Europeans necessitates further studies with improved power and sensitivity. Compared with array-based genotyping, whole-genome sequencing (WGS) data provide better coverage of the genome and better representation of non-European variants. To better understand the genetic landscape regulating plasma fibrinogen levels, we meta-analyzed WGS data from the National Heart, Lung, and Blood Institute’s Trans-Omics for Precision Medicine (TOPMed) program (n = 32 572), with array-based genotype data from the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (n = 131 340) imputed to the TOPMed or Haplotype Reference Consortium panel. We identified 18 loci that have not been identified in prior genetic studies of fibrinogen. Of these, 4 are driven by common variants of small effect with reported minor allele frequency (MAF) at least 10 percentage points higher in African populations. Three signals (SERPINA1, ZFP36L2, and TLR10) contain predicted deleterious missense variants. Two loci, SOCS3 and HPN, each harbor 2 conditionally distinct, noncoding variants. The gene region encoding the fibrinogen protein chain subunits (FGG;FGB;FGA) contains 7 distinct signals, including 1 novel signal driven by rs28577061, a variant common in African ancestry populations but extremely rare in Europeans (MAFAFR = 0.180; MAFEUR = 0.008). Through phenome-wide association studies in the VA Million Veteran Program, we found associations between fibrinogen polygenic risk scores and thrombotic and inflammatory disease phenotypes, including an association with gout. Our findings demonstrate the utility of WGS to augment genetic discovery in diverse populations and offer new insights for putative mechanisms of fibrinogen regulation.
Foramen Ovale Pulsatility Index as an Early Affected Doppler Study among Abnormal Growth Fetuses: A Recent Insight for Practice Based on a Prospective Study
Azam Faraji, Fereshteh Gharibpour, Niloofar Namazi, Ali Shakiba, Maryam Kasraeian, et al.
Iranian Journal of Medical Sciences, 2024
Background: Routine Doppler study is a common tool for early diagnosis of Fetal Growth Restriction (FGR) and Small for Gestational Age (SGA) patients. It aimed to determine the role of the Foramen Ovale Pulsatility Index (FOPI) study beside routine Doppler study among patients with FGR and SGA fetuses. Methods: This prospective study was conducted on 35 FGR, 32 SGA, and 33 Appropriate for Gestational Age (AGA) fetuses. Demographic data, amniotic fluid index, neonatal outcome, and Doppler velocimetry, including Umbilical Artery Pulsatility Index (UMAPI), Uterine Artery Pulsatility Index (UTAPI), Middle Cerebral Artery Pulsatility Index (MCAPI), Ductus Venosus Pulsatility Index (DVPI), and FOPI were documented. Kolmogorov-Smirnov normality test, one-way ANOVA, Mann-Whitney U, Kruskal-Wallis, non-parametric pairwise comparisons adjusted for Bonferroni correction, Pearson correlation test, Chi square, Fisher's exact test, and Receiver Operating Characteristic Curve (ROC) analysis with Youden's Index (sensitivity+specificity-1) to estimate cut-off point were used to analyze the data at significance level <0.05 for all tests. Results: FOPI cut-off points were 2.24 (sensitivity=77%, specificity=94%) and 1.15 (sensitivity=90%, specificity=20%) to predict FGR and SGA, respectively. FOPI showed a positive correlation with UMAPI and UTAPI (r=0.52 and r=0.30, P<0.001 and P=0.006, respectively), but not with MCAPI and DVPI (r=0.08 and r=0.12, P=0.50 and P=0.30, respectively). Besides, UMAPI, UTAPI, and FOPI were altered among patients with stages I and II FGR. Umbilical cord potential hydrogen (umbilical cord pH), 1- and 5-min Apgar score significantly increased by Birth weight centile; however, UMAPI, FOPI, and UTAPI significantly decreased. Conclusion: UMAPI is recommended to predict short-term neonatal morbidities and demonstrate the early or late onset FGR. Besides, FOPI is suggested as the first-line Doppler study to detect abnormal growth velocity. More studies are warranted, especially considering long-term neonatal morbidities.
Diagnosis of hydatidiform moles using p57 immunohistochemistry and chromogenic insitu hybridization: A retrospective study
Mojgan Akbarzadeh-Jahromi, Tara Taheri, Fatemeh Sari Aslani, Akbar Safaei, Fatemeh Pouraminaee, Marjan Zare
International Journal of Reproductive Biomedicine, 2024
Background: Chromogenic in situ hybridization (CISH) and immunohistochemistry analysis for p57 are ancillary studies discriminating partial hydatidiform mole (PHM), complete hydatidiform mole (CHM), and non-molar hydropic abortion (HA).Objective: It aimed to study CISH with a probe to chromosome 17 (CISH17) and chromosome 2 (CISH2) discriminating chromosomal ploidy of PHM, CHM, and HA; in addition, their surrogacy value in the evaluation of triploid and diploid in product of conception specimens (POCs) was evaluated.Materials and Methods: 44 statistically significant POCs were selected retrospectively. The Kappa agreement coefficients, sensitivity, specificity, and accuracy with 95% confidence interval (95% CI) were reported.Results: PHM, CHM, and HA were diagnosed to be 23, 17, and 3 cases based on both CISH2 and CISH17 resulting in their complete discrimination between PHM and HA (23 vs. 3). The Kappa agreement coefficient was 95.4% (p < 0.001) when diagnosing the PHM (23), CHM (20), and HA (1). In addition, the accuracy, sensitivity, and specificity were 95.26% (95% CI: 84.25–99.38), 100% (95% CI: 85.18–100), and 95% (95% CI: 76.18–99.88), respectively. The power analysis on CISH2 and CISH17 tests discriminating between triploid and diploid in POCs was estimated to be 100%.Conclusion: Based on the current finding, CISH2 and CISH17 enjoyed perfect agreement in diagnosing chromosomal ploidy; in addition, their absolute power discriminating between triploid and diploid revealed that they could be used as surrogate markers for ploidy. Prospective studies on fresh specimens are suggested comparing the CISH method’s accuracy with flow cytometry karyotyping and fluorescence in situ hybridization.Key words: Hydatidiform mole, CISH protein, Human, Pathology, Clinical.
Kharameh cohort study (KHCS) on noncommunicable diseases and preliminary findings of 3-year follow-up
Abbas Rezaianzadeh, Hamid Reza Niazkar, Ramin Rezaeianzadeh, Fatemeh Jafari, Salar Rahimikazerooni, Masoumeh Ghoddusi Johari, Marjan Zare, Seyed Vahid Hosseini
BMJ Open, 2024
PurposeThe Kharameh cohort study (KHCS) is one branch of the ‘Prospective Epidemiological Research Studies in Iran’, located in the south of Iran. The enrolment phase of KHCS spanned from April 2015 to March 2017, during which urban and rural residents of Kharameh were enrolled in the study. KHCS aims to investigate the incidence of non-communicable diseases (NCDs) such as hypertension, diabetes mellitus, cardiovascular diseases and cancer, and its related risk factors in a 15-year follow-up.ParticipantsKHCS was designed to recruit 10 000 individuals aged 40–70 years old from both urban and rural areas of Kharameh. Thus, a total of 10 800 individuals aged 40–70 years of age were invited and, finally, 10 663 subjects were accepted to participate, with a participation rate of 98.7%.Findings to dateOf the 10 663 participants, 5944 (55.7%) were women, and 6801 (63.7%) were rural residents. The mean age of the participants was 51.9±8.2 years. 41.8% of the participants were aged 40–49, 35.2% were aged 50–59 and the remaining 23% were 60–70 years old. Until March 2020 (first 3 years of follow-up), the total number of patients diagnosed with NCDs was 1565. Hypertension, type 2 diabetes and acute ischaemic heart disease were the most common NCDs. Furthermore, the total number of deaths during the first 3 years of follow-up was 312, with cardiovascular diseases (38.7%) as the most common cause of death, followed by cerebrovascular diseases (11.8%) and cancer (16.2%).Future plansThe remaining 12 years of follow-up will inevitably shed light on the genetic, lifestyle/socioeconomic status, and environmental risk and protective factors of NCDs.
Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis
Louise Ghesquiere, Paul Guerby, Isobel Marchant, Namrata Kumar, Marjan Zare, Marie-Anne Foisy, Stéphanie Roberge, Emmanuel Bujold
American Journal of Obstetrics and Gynecology Mfm, 2023
Comparison of in-hospital mortality of COVID-19 between pregnant and non-pregnant women infected with SARS-CoV-2: A historical cohort study
Marjan Zare, Alireza Mirahmadizadeh, Mahsa Akbari, Mohammad Javad Moradian
Journal of Perinatal Medicine, 2023
Objectives This study aimed to compare pregnant and non-pregnant women infected with SARS-CoV-2 disease (COVID-19) in terms of in-hospital mortality. Methods This historical cohort study was conducted on hospitalized women of reproductive ages (15–49 years) infected with SARS-CoV-2 in Fars province, Iran during 15 March 2019–10 May 2021. Results Out of the 5,322 patients, 330 were pregnant. The fatality rate of SARS-CoV-2 was 1.2% amongst pregnant women and 3.5% amongst non-pregnant ones. Pregnant and non-pregnant women reported the same history of smoking, opium use, previous COVID-19 infection, vaccination against SARS-CoV-2, and COVID-19 symptoms (p>0.05 for all). However, the pregnant women were younger and had fewer underlying diseases (p<0.001 for both). The results revealed no significant difference between the two groups regarding in-hospital clinical manifestations including the number of days after the onset of COVID-19 symptoms, mechanical ventilation, and long involvement (cRR; 95% CI=0.99 (0.96–1.02), 1.18 (0.72–2.02), and 0.95 (0.88–1.02), respectively). Nonetheless, Intensive Care Unit (ICU) admission was significantly higher in pregnant women (cRR; 95% CI=2.37(1.85–3.02)). After adjusting for age, history of underlying diseases, and ICU admission, pregnant women showed lower in-hospital mortality due to COVID-19 compared to non-pregnant women (aRR; 95% CI=0.32 (0.12–0.87)). Conclusions Based on the current study findings, pregnant women showed lower in-hospital mortality due to COVID-19 compared to non-pregnant ones. Nevertheless, they should follow the same recommendations as non-pregnant women, avoiding exposure to the virus and receiving medical treatment and vaccination. Further studies are recommended to address the follow-up of recovered pregnant women, their babies, and puerperium.
Comparison of Time to Report the Side Effects after AstraZeneca and Sinopharm Vaccinations in Users of the COVID-19 Symptom Study App: A Survey in South Iran
Marjan Zare, Alireza Mirahmadizadeh, Masoumeh Khosravi, Mohammadreza Karimi, Seyedeh Leila Dehghani
Medical Journal of the Islamic Republic of Iran, 2023
Background: Concerns about the side effects of SARS-CoV-2 vaccines have been raised nationwide. We aimed to compare the time to report the side effects of the Oxford-AstraZeneca and Sinopharm COVID-19 vaccines. Methods: Information on side effects of AstraZeneca and Sinopharm COVID-19 vaccines was obtained from the COVID-19 Symptom Study App affiliated with Shiraz University of Medical Science during 2021. A COX regression model with an adjusted Hazard Ratio and 95% Confidence Interval; HR (95% C.I) was reported at the significance level of < 0.05. Results: < 0.05 for both). There was significantly less time to pain HR(95% C.I.); 0.50 (0.47-0.52), vertigo 0.65 (0.61-0.69), weakness 0.41 (0.38-0.44), headache 0.43 (0.39-0.74), anorexia 0.31 (0.28-0.34), nausea 0.56 (0.51-0.62), severer allergy 0.71 (0.63-0.81), general inflammation 0.27 (0.23-0.31), fever > 38oC 0.12 (0.1-0.15), eye inflammation 0.45 (0.39-0.52), diarrhea 0.85 (0.73-0.99), blurred vision 0.73 (0.61-0.86), injection site redness 0.32 (0.26-0.39), fatigue/paleness 0.53 (0.50-0.57), joint pain 0.55 (0.41-0.73), auxiliary gland inflation 0.59 (0.43-0.80), convulsions 0.30 (0.17-0.52), and severe side effects 0.3 (0.27-0.33) in the AstraZeneca group; However, skin rash 0.77 (0.57-1.05) and hospitalization 0.72 (0.21-2.55) were the same. Conclusion: Sinopharm COVID-19 vaccine recipients reported longer times to report vaccine-related side effects than AstraZeneca; due to the lack of adverse effects like hospitalization, vaccination should continue to control the pandemic; more real-population studies are needed on the long-term effects of vaccination against COVID-19.
The Prevalence of Human Papilloma Virus Infection and Its High Risk Genotypes among Healthy Women in 28 Provinces in Iran: A Systematic Review and Meta-Analysis
Mojgan Akbarzadeh-Jahromi, Negar Taheri, Babak Dashtdar, Nasim Taheri, Fatemeh Abiri, Marjan Zare
Journal of Biostatistics and Epidemiology, 2023
The effect of 150 and 80 mg doses of aspirin on preventing preterm birth in high-risk pregnant women
Maryam Kasraeian, Nasrin Asadi, Homeira Vafaei, Mahin Tazang, Azam Faraji, Neda Rahimirad, Sedighe Yousofi, Seyedeh Fatemeh Khaleghi, Marjan Zare
Journal of Perinatal Medicine, 2022
Reply to: Aspirin for the prevention of preeclampsia
Maryam Kasraeian, Nasrin Asadi, Homeira Vafaei, Mahin Tazang, Azam Faraji, Neda Rahimirad, Sedighe Yousofi, Seyedeh Fatemeh Khaleghi, Marjan Zare
Journal of Perinatal Medicine, 2022
Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial
Alireza Mirahmadizadeh, Ali Semati, Alireza Heiran, Mostafa Ebrahimi, Abdolrasool Hemmati, Mohammadreza Karimi, Souzan Basir, Marjan Zare, Antonio Charlys da Costa, Mohammad Zeinali, Maryam Sargolzaee, Owrang Eilami
Respirology, 2022
Epidemiological Study of Infection and Death Due to COVID-19 in Fars Province, Iran, From February to September 2020
Ali Semati, Marjan Zare, Alireza Mirahmadizadeh, Abdulrasool Hemmati, Mostafa Ebrahimi
Iranian Journal of Medical Sciences, 2022
Spatial epidemiology and meteorological risk factors of COVID-19 in Fars Province, Iran
Marjan Zare, Ali Semati, Alireza Mirahmadizadeh, Abdulrasool Hemmati, Mostafa Ebrahimi
Geospatial Health, 2022
Spatiotemporal Study of COVID-19 in Fars Province, Iran, October-November 2020: Establishment of Early Warning System
Ali Semati, Azimeh Zare, Marjan Zare, Alireza Mirahmadizadeh, Mostafa Ebrahimi
Canadian Journal of Infectious Diseases and Medical Microbiology, 2022
COVID-19 pneumonia and pregnancy; a systematic review and meta-analysis
Maryam Kasraeian, Marjan Zare, Homeira Vafaei, Nasrin Asadi, Azam Faraji, Khadijeh Bazrafshan, Shohreh Roozmeh
Journal of Maternal Fetal and Neonatal Medicine, 2022
Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum
Azam Faraji, Mojgan Akbarzadeh-Jahromi, Shima Bahrami, Sayeh Gharamani, Hadi Raeisi Shahraki, Maryam Kasraeian, Homeira Vafaei, Marjan Zare, Nasrin Asadi
Journal of Obstetrics and Gynaecology, 2022
The impact of betamethasone on fetal pulmonary, umbilical and middle cerebral artery Doppler velocimetry and its relationship with neonatal respiratory distress syndrome
Homeira Vafaei, Fahimeh Kaveh Baghbahadorani, Nasrin Asadi, Maryam Kasraeian, Azam Faraji, Shohreh Roozmeh, Marjan Zare, Khadije Bazrafshan
BMC Pregnancy and Childbirth, 2021
Determining endemic values of cutaneous leishmaniasis in Iranian Fars province by retrospectively detected clusters and receiver operating characteristic curve analysis
Abbas Rezaianzadeh, Marjan Zare, Hamidreza Tabatabaee, Hossain Faramarzi, Mohsen Aliakbarpour, Mostafa Ebrahimi
Asian Pacific Journal of Tropical Biomedicine, 2019
Establishment of an early warning system for cutaneous leishmaniasis in Fars province, Iran
Abbas Rezaianzadeh, Marjan Zare, Hamidreza Tabatabaee, Hossain Faramarzi, Mohsen Aliakbarpour, Mostafa Ebrahimi
Asian Pacific Journal of Tropical Biomedicine, 2019
Does prospective permutation scan statistics work well with cutaneous leishmaniais as a high-frequency or malaria as a low-frequency infection in Fars province, Iran?
Marjan Zare, Abbas Rezaianzadeh, Hamidreza Tabatabaee, Mohsen Ali-Akbarpour, Hossain Faramarzi, Mostafa Ebrahimi
Asian Pacific Journal of Tropical Biomedicine, 2018
Spatiotemporal clustering of cutaneous leishmaniasis in Fars province, Iran
Marjan Zare, Abbas Rezaianzadeh, Hamidreza Tabatabaee, Mohsen Aliakbarpoor, Hossein Faramarzi, Mostafa Ebrahimi
Asian Pacific Journal of Tropical Biomedicine, 2017

Marjan Zare

EDUCATION

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS

RESEARCH OUTPUTS (PATENTS, SOFTWARE, PUBLICATIONS, PRODUCTS)

Industry, Institute, or Organisation Collaboration